Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments?

被引：3

作者：

Chang C.C. ^{[1
]}

Chen S.C.-A. ^{[2
,3
]}

机构：

[1] Department of Infectious Diseases, Alfred Hospital, Monash University, Melbourne

[2] Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, Sydney

[3] Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, New South Wales Health Pathology, Westmead Hospital, 3rd Level, ICPMR Building, Darcy Road, Westmead, 2145, NSW

来源：

Current Fungal Infection Reports | 2018年 / 12卷 / 2期

关键词：

Contact lens infection; Fungal endophthalmitis; Fungal keratitis; Invasive fungal infection; Mycotic ulcer; Topical natamycin; Voriconazole;

D O I：

10.1007/s12281-018-0315-z

中图分类号：

学科分类号：

摘要：

Purpose of Review: We sought to explore the current incidence and associated risk factors associated with fungal eye infections. We also reviewed new diagnostic strategies and recent clinical studies exploring the use of topical and oral antifungal agents. Recent Findings: Incidence and associated risks continue to vary with geographic region, and access to timely healthcare. Nosocomial fungal endophthalmitis can result from minor surgical procedures to the eye. Molecular methods offer increasing diagnostic utility. Clinical treatment studies have mainly focussed on the treatment of fungal keratitis and have been conducted in South Asia. Topical natamycin remains superior to topical reconstituted voriconazole and remains the preferred therapy including for Fusarium eye infections. Neither adjunctive oral ketoconazole nor oral voriconazole has been shown to have added clear benefit to topical treatment. Summary: Larger international studies with more heterogenous populations are required for future clinical studies which should include patients with contact lens fungal keratitis and those with fungal endophthalmitis. Basic science studies exploring the immunology of fungal eye infections and drug levels to understand the differences in clinical outcomes are encouraged. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

引用

页码：66 / 70

页数：4

共 24 条

[1]

Lalitha P., Prajna N.V., Manoharan G., Srinivasan M., Mascarenhas J., Das M., D'Silva S.S., Porco T.C., Keenan J.D., Trends in bacterial and fungal keratitis in South India, 2002-2012, Br J Ophthalmol, 99, 2, pp. 192-194, (2015)

[2]

Aruljyothi L., Radhakrishnan N., Prajna V.N., Lalitha P., Clinical and microbiological study of paediatric infectious keratitis in South India: a 3-year study (2011-2013), Br J Ophthalmol, 100, 12, pp. 1719-1723, (2016)

[3]

Durand M.L., Bacterial and fungal endophthalmitis, Clin Microbiol Rev, 30, 3, pp. 597-613, (2017)

[4]

Schimel A.M., Miller D., Flynn H.W., Endophthalmitis isolates and antibiotic susceptibilities: a 10-year review of culture-proven cases, Am J Ophthalmol, 156, 1, pp. 50-52, (2013)

[5]

Kainer M.A., Reagan D.R., Nguyen D.B., Wiese A.D., Wise M.E., Ward J., Park B.J., Kanago M.L., Baumblatt J., Schaefer M.K., Berger B.E., Marder E.P., Min J.Y., Dunn J.R., Smith R.M., Dreyzehner J., Jones T.F., Fungal infections associated with contaminated methylprednisolone in Tennessee, N Engl J Med, 367, 23, pp. 2194-2203, (2012)

[6]

Kauffman C.A., Pappas P.G., Patterson T.F., Fungal infections associated with contaminated methylprednisolone injections, N Engl J Med, 368, 26, pp. 2495-2500, (2013)

[7]

Edison L.S., Dishman H.O., Tobin-D'Angelo M.J., Allen C.R., Guh A.Y., Drenzek C.L., Endophthalmitis outbreak associated with repackaged bevacizumab, Emerg Infect Dis, 21, 1, pp. 171-173, (2015)

[8]

Rayess N., Rahimy E., Storey P., Shah C.P., Wolfe J.D., Chen E., DeCroos F.C., Garg S.J., Hsu J., Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept, Am J Ophthalmol, 165, pp. 88-93, (2016)

[9]

Forooghian F., Albiani D.A., Kirker A.W., Merkur A.B., Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept, Can J Ophthalmol, 52, 6, pp. 616-619, (2017)

[10]

Al-Rashaed S., Et al., Incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor: experience in Saudi Arabia, Middle East Afr J Ophthalmol, 23, 1, pp. 60-63, (2016)

← 1 2 3 →